Effect of major deletions in the V1 and V2 loops of a macrophage-tropic HIV type 1 isolate on viral envelope structure, cell entry, and replication

AIDS Research and Human Retroviruses

Volumn 14, Issue 13, 1998, Pages 1129-1139

  Stamatatos, L ^a,b   Wiskerchen, M ^a   Cheng Mayer, C ^a  

^a ROCKEFELLER UNIVERSITY   (United States)

^b AARON DIAMOND AIDS RESEARCH CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID; CD4 ANTIGEN; EPITOPE; GLYCOPROTEIN GP 120; VIRUS ENVELOPE PROTEIN;

AMINO ACID SEQUENCE; ARTICLE; CONFORMATIONAL TRANSITION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOCHEMISTRY; MACROPHAGE; NONHUMAN; PRIORITY JOURNAL; VIRION; VIRUS ENVELOPE; VIRUS GENOME; VIRUS REPLICATION;

EID: 0032169683     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/aid.1998.14.1129     Document Type: Article

References (48)

1. Sattentau QJ and Moore JP: Conformational changes induced in the human immunodeficiency virus envelope glycoprotein by soluble CD4 binding. J Exp Med 1991;174:407-415.
2. Sattentau QJ, Moore JP, Vignaux F, Traincard F, and Poignard P: Conformational changes induced in the envelope glycoproteins of the human and simian immunodeficiency viruses by soluble receptor binding. J Virol 1993;67:7383-7393.
3. Stamatatos L and Cheng-Mayer C: Structural modulations of the envelope gp120 glycoprotein of human immunodeficiency virus type 1 upon oligomerization and differential V3 loop epitope exposure of isolates displaying distinct tropism upon virion-soluble receptor binding. J Virol 1995;69:6191-6198.
4. Sullivan N, Sun Y, Li J, Hofmann W, and Sodroski J: Replicative function and neutralization sensitivity of envelope glycoproteins from primary and T-cell line-passaged human immunodeficiency virus type 1 isolates. J Virol 1995;69:4413-4422.
5. Stamatatos L, Werner A, and Cheng-Mayer C: Differential regulation of cellular tropism and sensitivity to soluble CD4 neutralization by the envelope gp120 of human immunodeficiency virus type 1. J Virol 1994;68:4973-4979.
6. Stamatatos L, Zolla-Pazner S, Gorny M, and Cheng-Mayer C: Binding of antibodies to virion-associated gp120 molecules of primary-like human immunodeficiency virus type 1 (HIV-1) isolates: Effect on HIV-1 infection of macrophages and peripheral blood mononuclear cells. Virology 1997;229:360-369.
7. Wyatt R, Sullivan N, Thali M, Repke H, Ho D, Robinson J, Posner M, and Sodroski J: Functional and immunologic characterization of human immunodeficiency virus type 1 envelope glycoproteins containing deletions of the major variable regions. J Virol 1993;67:4557-4565.
8. Wyatt R, Moore J, Accola M, Desjardin E, Robinson J, and Sodroski J: Involvement of the V1/V2 variable loop structure in the exposure of human immunodeficiency virus type 1 gp120 epitopes induced by receptor binding. J Virol 1995;69:5723-5733.
9. Sattentau QJ, Zolla-Pazner S, and Poignard P: Epitope exposure on functional, oligomeric HIV-1 gp41 molecules. Virology 1995; 206:713-717.
10. Moore JP, McKeating JA, Huang Y, Askenazi A, and Ho DD: Virions of primary human immunodeficiency virus type 1 isolates resistant to soluble CD4 (sCD4) neutralization differ in sCD4 binding and glycoprotein gp120 retention from sCD4-sensitive isolates. J Virol 1992;66:235-243.
11. Bou-Habib DC, Roderiquez G, Oravesz T, Berman PW, Lusso P, and Norcross MA: Cryptic nature of envelope V3 region epitopes protects primary monocytotropic human immunodeficiency virus type 1 from antibody neutralization. J Virol 1994;68:6006-6013.
12. Moore JP, Sattentau QJ, Yoshiyama H, Thali M, Charles M, Sullivan N, Poon S-W, Fung MS, Traincard F, Pinkus M, Robey G, Robinson JE, Ho DD, and Sodroski J: Probing the structure of the V2 domain of human immunodeficiency virus type 1 surface glycoprotein gp120 with a panel of eight monoclonal antibodies: Human immune response to the V1 and V2 domains. J Virol 1993;67:6136-6151.
13. Moore JP, Thali M, Jameson BA, Vignaux F, Lewis GK, Poon S-W, Fung MS, Sun B, Durda PJ, Akerblom L, Wahren B, Ho DD, Sattentau QJ, and Sodroski J: Immunochemical analysis of the gp120 surface glycoprotein of human immunodeficiency virus type 1: Probing the structure of C4 and V4 domains and the interaction of the C4 domain with the V3 loop. J Virol 1993;67:4785-4796.
14. Chesebro B, Wehrly K, Nishio J, and Perryman S: Macrophagetropic human immunodeficiency virus isolates from different patients exhibit unusual V3 envelope sequence homogeneity in comparison with T-cell-tropic isolates: Definition of critical amino acids involved in cell tropism. J Virol 1992;66:6547-6554.
15. Javaherian K, Langlois AJ, McDanal C, Ross KL, Eckler LI, Jellis CL, Profy AT, Rusche JR, Bolognesi DP, Putney SD, and Matthews TJ: Principal neutralizing domain of the human immunodeficiency virus type 1 envelope protein. Proc Natl Acad Sci USA 1989;86:6768-6772.
16. Moore JP and Nara PL: The role of the V3 loop of gp120 in HIV infection. AIDS 1991;5:S21-33.
17. O'Brien WA, Koyanagi Y, Namazie A, Zhao J-Q, Diagne A, Idler K, Zack JA, and Chen ISY: HIV-1 tropism for mononuclear phagocytes can be determined by regions of gp120 outside the CD4-binding domain. Nature (London) 1990;346:69-73.
18. Rusche JR, Javaherian K, McDanal C, Petro J, Lynn DL, Grimaila R, Langlois A, Gallo RC, Arthur LO, Fischinger PJ, Bolognesi DP, Putney SD, and Matthews TJ: Antibodies that inhibit fusion of human immunodeficiency virus-infected cells bind a 24-amino acid sequence of the viral envelope, gp120. Proc Natl Acad Sci USA 1988;85:3198-3202.
19. Shioda T, Levy JA, and Cheng-Mayer C: Small amino acid changes in the V3 hypervariable region of gp120 can affect the T-cell line and macrophage tropism of human immunodeficiency virus type 1. Proc Natl Acad Sci USA 1992;89:9434-9438.
20. Takeuchi Y, Akutsu M, Murayama K, Shimizu N, and Hoshino H: Host range mutant of human immunodeficiency virus type 1: Modification of cell tropism by a single point mutation at the neutralizing epitope in the env gene. J Virol 1991;65:1710-1718.
21. Westervelt P, Trowbridge DB, Epstein LG, Blumberg BM, Li Y, Hahn BH, Shaw GM, Price RW, and Ratner L: Macrophate tropism determinants of human immunodeficiency virus type 1 in vivo. J Virol 1992;66:2577-2582.
22. Carrilo A and Ratner L: Cooperative effects of the human immunodeficiency virus type 1 envelope variable loops V1 and V3 in mediating infectivity for T cells. J Virol 1996;70:1310-1316.
23. Andeweg AC, Leeflang P, Osterhaus ADME, and Bosch ML: Both the V2 and V3 regions of the human immunodeficiency virus type 1 surface glycoprotein functionally interact with other envelope regions in syncytium formation. J Virol 1993;67:3232-3239.
24. Koito A, Harrowe G, Levy JA, and Cheng-Mayer C: Functional role of the V1/V2 region of human immunodeficiency virus type 1 envelope glycoprotein gp120 in infection of primary macrophages and soluble CD4 neutralization. J Virol 1994;68: 2253-2259.
25. Koito A, Stamatatos L, and Cheng-Mayer C: Small amino acid sequence changes within the V2 domain can affect the function of a T-cell line-tropic human immunodeficiency virus type 1 envelope gp120. Virology 1995;206:878-884.
26. Palmer C, Balfe P, Fox D, May JC, Frederiksson R, Fenyö ME, and McKeating JA: Functional characterization of the V1V2 region of human immunodeficiency virus type 1. Virology 1996; 220:436-449.
27. Toohey K, Wehrly K, Nishio J, Ferryman S, and Chesebro B: Human immunodeficiency virus envelope V1 and V2 regions influence replication efficiency in macrophages by affecting virus spread. Virology 1995;213:70-79.
28. Cho MW, Shibata R, and Martin MA: Infection of chimpanzee peripheral blood mononuclear cells by human immunodeficiency virus type 1 requires cooperative interaction between multiple variable regions of gp120. J Virol 1996;70:7318-7321.
29. Fox DG, Balfe P, Palmer CP, May JC, Arnold C, and McKeating JA: Length polymorphism within the second variable region of the human immunodeficiency virus type 1 envelope glycoprotein affects accessibility of the receptor binding site. J Virol 1997;71: 759-765.
30. Cheng-Mayer C, Homsy J, Evans LA, and Levy JA: Identification of human immunodeficiency virus subtypes with distinct patterns of sensitivity to serum neutralization. Proc Natl Acad Sci USA 1988;85:2815-2819.
31. Moore JP and Ho DD: HIV-1 neutralization: The consequences of viral adaptation to growth on transformed T cells. AIDS 1995; 9:117-136.
32. Gorny MK, Moore JP, Conley AJ, Karwowska S, Sodroski J, Williams C, Burda S, Boots LJ, and Zolla-Pazner S: Human anti-V2 monoclonal antibody that neutralizes primary but not laboratory isolates of human immunodeficiency virus type 1. J Virol 1994;68:8312-8320.
33. Gorny MK, Xu J-Y, Karwowska S, Buchbinder A, and Zolla-Pazner S: Repertoire of neutralizing human monoclonal antibodies specific for the V3 domain of HIV-1 gp120. J Immunol 1993; 150:635-643.
34. Seligman SJ, Binley JM, Gorny MK, Burton DR, Zolla-Pazner S, and Sokolowski KA: Characterization by serial competition ELISAs of HIV-1 V3 loop epitopes recognized by monoclonal antibodies. Mol Immunol 1996;33:737-745.
35. Laal S, Burda S, Gorny MK, Karwowska S, Buchbinder A, and Zolla-Pazner S: Synergistic neutralization of human immunodeficiency virus type 1 by combinations of human monoclonal antibodies. J Virol 1994;68:4001-4008.
36. Fung MSC, Sun CRY, Gordon WL, Liu RS, Chang TW, Sun WNC, Daar ES, and Ho DD: Identification and characterization of a neutralization site within the second variable region of human immunodeficiency virus type 1. J Virol 1992;66:848-856.
37. Burton DR, Pyati J, Koduri R, Sharp SJ, Thorton GB, Parren PHI, Sawyer LSW, Hendry RM, Dunlop N, Nara PL, Lamacchia M, Garratty E, Stiehm ER, Bryson YJ, Cao Y, Moore JP, Ho DD, and Barbas CF III: Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody. Science 1994; 266:1024-1027.
38. Roben P, Moore JP, Thali M, Sodroski J, Barbas CF III, and Burton DR: Recognition properties of a panel of human recombinant Fab fragments to the CD4 binding site of gp120 that show differing abilities to neutralize human immunodeficiency virus type 1. J Virol 1994;68:4821-4828.
39. Capon DJ, Chamow SM, Mordenti J, Marsters SA, Gregory T, Mitsuya H, Byrn RA, Lucas C, Wurm FM, Groopman JE, Broder S, and Smith DH: Designing CD4 immunoadhesions for AIDS therapy. Nature (London) 1989;337:525-531.
40. Cheng-Mayer C, Quiroga M, Tung JW, Dina D, and Levy J: Viral determinants of human immunodeficiency virus type 1 T-cell or macrophage tropism, cytopathogenicity, and CD4 antigen modulation. J Virol 1990;64:4390-4398.
41. Cheng-Mayer C, Liu R, Landau NR, and Stamatatos L: Macrophage tropism of HIV-1 and utilization of the CC-CKR5 coreceptor. J Virol 1997;71:1657-1661.
42. Niwa H, Yamamura KI, and Miyazaki JI: Efficient selection for high-expression transfectants with a novel eukaryotic vector. Gene 1991;108:193-200.
43. Connor TI, Chen BK, Choe S, and Landau NR: Vpr is required for efficient replication of human immunodeficiency virus type 1 in mononuclear phagocytes. Virology 1995;206:1772-1777.
44. Mo H, Stamatatos L, Ip JE, Barbas CF, Parren PWHI, Burton DR, Moore JP, and Ho DD: Human immunodeficiency virus type 1 mutants that escape neutralization by human monoclonal antibody IgG1b12. J Virol 1997;71:6869-6874.
45. Thali M, Moore JP, Furma C, Charles M, Ho DD, Robinson J, and Sodroski J: Characterization of conserved human immunodeficiency virus type 1 gp120 neutralization epitopes exposed upon gp120-CD4 binding. J Virol 1993;67:3978-3988.
46. Trkola A, Dragic T, Arthos J, Binley JM, Olson WC, Allaway GP, Cheng-Mayer C, Robinson J, Maddon PJ, and Moore JP: CD4-dependent, antibody-sensitive interactions between HIV-1 and its co-receptor CCR5. Nature (London) 1996;384:184-187.
47. Wu L, Gerard NP, Wyatt R, Choe H, Parolin C, Ruffing N, Borsetti A, Cardoso AA, Desjardin E, Newman W, Gerard C, and Sodroski J: CD4-induced interaction of primary HIV-1 gp120 glycoproteins with the chemokine receptor CCR5. Nature (London) 1996; 384:179-183.
48. Collman R, Godfrey B, Cutilli J, Rhodes A, Hassan NF, Sweet R, Douglas DD, Friedman H, Nathason N, and Gonzalez-Scarano F: Macrophage-tropic strains of human immunodeficiency virus type 1 utilize the CD4 receptor. J Virol 1990;64:4468-4476.